This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (17) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kruger, D. F. Articles by Owen, S. K. Search for Related Content PubMed PubMed Citation Articles by Kruger, D. F. Articles by Owen, S. K. Social Bookmarking                         What's this?

Clinical Implications of Amylin and Amylin Deficiency

Division of Endocrinology and Metabolism, Henry Ford Health System, 2799 West Grand Boulevard, Detroit MI 48202 DKRUGER{at}diabetes.org

Patricia M. Gatcomb, RN, CDE

Yale University, Department of Pediatric Endocrinology, New Haven, Connecticut

Susan K. Owen, MSN, RN, CDE

Grand Rapids Associated Internists, Grand Rapids, Michigan

PURPOSE

this paper presents an overview of the physiology of glycemic control and the mechanisms of amylin deficiency in people with diabetes. Benefits of replacement therapy with both pramlintide and insulin are discussed.

METHODS

The discovery of the pancreatic p-cell hormone amylin, which is cosecreted with insulin in response to hyperglycemia, has prompted a reanalysis of the mechanisms underlying the control of glucose homeostasis. A review of the current literature on amylin and amylin deficiency provides the basis of this reanalysis, with a discussion of the clinical implications for people with diabetes.

RESULTS

Amylin appears to work with insulin to regulate plasma glucose concentrations in the bloodstream, suppressing the postprandial secretion of glucagon and restraining the rate of gastric emptying. People with diabetes have a deficiency in the secretion of amylin that parallels the deficiency in insulin secretion, resulting in an excessive inflow of glucose into the bloodstream during the postprandial period.

CONCLUSIONS

While insulin replacement therapy is a cornerstone of diabetes treatment, replacement of the function of both amylin and insulin may allow a more complete restoration of the normal physiology of glucose control.

The Diabetes Educator, Vol. 25, No. 3, 389-397 (1999)
DOI: 10.1177/014572179902500310


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. T. Meade Practical Use of Exenatide and Pramlintide for the Treatment of Type 2 Diabetes Journal of Pharmacy Practice, December 1, 2009; 22(6): 540 - 545. [Abstract] [PDF]

				S. V. Edelman Optimizing Diabetes Treatment Using an Amylin Analogue The Diabetes Educator, January 1, 2008; 34(1_suppl): 4S - 10S. [Abstract] [Full Text] [PDF]

				T. A. Kellmeyer, N. C. Kesty, Y. Wang, J. P. Frias, and M. S. Fineman Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times Relative to Subcutaneous Injection of Pramlintide in Subjects With Type 2 Diabetes J. Clin. Pharmacol., July 1, 2007; 47(7): 798 - 805. [Abstract] [Full Text] [PDF]

				D. F. Kruger, S. L. Aronoff, and S. V. Edelman Through the Looking Glass: Current and Future Perspectives on the Role of Hormonal Interplay in Glucose Homeostasis The Diabetes Educator, February 1, 2007; 33(Supplement_2): 32S - 46S. [Full Text] [PDF]

				P. S. Odegard, S. M. Setter, and J. L. Iltz Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide. The Diabetes Educator, September 1, 2006; 32(5): 693 - 712. [Abstract] [Full Text] [PDF]

				C. Martin The Physiology of Amylin and Insulin: Maintaining the Balance Between Glucose Secretion and Glucose Uptake The Diabetes Educator, May 1, 2006; 32(Supplement_3): 101S - 104S. [Abstract] [Full Text] [PDF]

				S. V. Edelman and L. Caballero Amylin Replacement Therapy in Patients With Type 1 Diabetes The Diabetes Educator, May 1, 2006; 32(Supplement_3): 119S - 127S. [Abstract] [Full Text] [PDF]

				D. F. Kruger, C. L. Martin, and C. E. Sadler New insights into glucose regulation. The Diabetes Educator, March 1, 2006; 32(2): 221 - 228. [Abstract] [Full Text] [PDF]

				S. L. Aronoff, K. Berkowitz, B. Shreiner, and L. Want Glucose Metabolism and Regulation: Beyond Insulin and Glucagon Diabetes Spectr, July 1, 2004; 17(3): 183 - 190. [Abstract] [Full Text] [PDF]

				C. K. Rayner, M. Samsom, K. L. Jones, and M. Horowitz Relationships of Upper Gastrointestinal Motor and Sensory Function With Glycemic Control Diabetes Care, February 1, 2001; 24(2): 371 - 381. [Abstract] [Full Text]